June 2022 in “Frontiers in Immunology” Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
1 citations
,
December 2023 in “Journal of the European Academy of Dermatology and Venereology”
December 2023 in “Biointerface Research in Applied Chemistry” Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.
July 1995 in “Journal of Dermatological Science” Cyclosporine starts hair growth faster, while minoxidil makes it last longer.
55 citations
,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
April 2025 in “Anais Brasileiros de Dermatologia” Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
September 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
April 2023 in “Medicina Clínica (english Edition)”
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
2 citations
,
September 2024 in “Expert Opinion on Drug Metabolism & Toxicology” Ritlecitinib is an effective new treatment for Alopecia Areata.
2 citations
,
December 2020 in “American Journal of Dermatological Research and Reviews” The combination therapy was effective and well-tolerated, especially in young patients.
48 citations
,
January 2011 in “International journal of trichology” Intralesional triamcinolone acetonide is the most effective treatment for localized alopecia areata.
December 2024 in “Frontiers in Pediatrics” Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
65 citations
,
April 1999 in “Journal of Parasitology” The topical treatment WR 279,396 effectively healed cutaneous leishmaniasis in mice without relapse.
1 citations
,
September 2025 in “Archivio Italiano di Urologia e Andrologia” Serenoa repens extract, alone or with other supplements, improves urinary symptoms and lowers PSA levels.
December 2025 in “PubMed” Baricitinib is effective and safe for treating severe alopecia areata.
8 citations
,
May 2017 in “Singapore Medical Journal” A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
3 citations
,
March 2022 in “Medicine” Systemic lupus erythematosus treatment can restore vision in patients with retinal artery occlusion.
2 citations
,
June 2020 in “Clinical Journal of Gastroenterology” Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
68 citations
,
May 2018 in “PLOS Biology” Cyclosporine A may help treat hair loss by blocking a protein that inhibits hair growth.
37 citations
,
August 2022 in “Frontiers in pharmacology” Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
1 citations
,
October 2023 in “Clinical, cosmetic and investigational dermatology” Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.
September 2023 in “Journal of the American Academy of Dermatology” Alopecia is rare after organ transplants but more common in females, Hispanic patients, and pancreas recipients.
June 2026 in “Dermatology and Therapy” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
65 citations
,
February 2015 in “Neuro-Oncology” Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
211 citations
,
May 2013 in “Journal of Nutrition Health & Aging” MK-0773 safely increased muscle mass but did not improve muscle strength or function in elderly women with sarcopenia.
10 citations
,
July 2002 in “Australasian Journal of Dermatology” Careful management of blood thinners is crucial for lupus patients with APS.